Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities
Biomolecules · 2026
DOI: 10.3390/biom16091260 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Alaa A El Moghrabi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut 1107-2020, Lebanon. Hauptthemen laut MEDLINE: Cannabinoids, Neoplasms. Die Arbeit nennt 246 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cannabinoids are terpenophenolic compounds derived from Cannabis sativa L. that exert a broad range of biological and pharmacological activities. Increasing evidence highlights their potential as modulators of cancer progression specifically through the suppression of tumor cell growth, angiogenesis, and metastasis across multiple tumor models. This review provides a comprehensive overview of the molecular mechanisms by which natural and synthetic cannabinoids induce regulated cancer cell death. Current evidence demonstrates that cannabinoids regulate multiple forms of cancer cell death, including apoptosis, autophagy-dependent cell death, necroptosis, ferroptosis, and parthanatos. These effects are mediated through complex and interconnected signaling pathways such as TRIB3/AKT/mTORC1, PI3K/AKT/mTOR, MAPK/ERK, NF-κB, ERK/JNK/p38-MAPK, and ceramide/Raf1/ERK/ROS. In addition to their direct antitumor effects, cannabinoids can enhance the efficacy of conventional anticancer therapies through the coordinated regulation of complementary cell death pathways. They also provide clinically relevant supportive benefits in palliative care, alleviating chemotherapy-induced nausea, cachexia, and mood or sleep disturbances. Collectively, these findings identify cannabinoids as promising anticancer agents and therapeutic adjuvants, predominantly in the preclinical setting. However, significant challenges remain regarding their safety, optimal dosing, formulation, and clinical efficacy. Further mechanistic studies, rigorous preclinical research, and well-designed clinical trials are required to establish the translation of cannabinoid-based therapies into precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut 1107-2020, Lebanon.
- Department of Experimental Pathology, Immunology and Microbiology, American University of Beirut, Beirut 1107-2020, Lebanon.
ORCID-Profile: Alaa A El Moghrabi, Ali Al Khatib, Israa Ahmad Cheikh, Charbel Al Hage, Dima Ismail, Mariam Zhour, Philip Mwesigwa, Nadine Darwiche
Zitieren
APA
El Moghrabi, A. A., Al Khatib, A., Cheikh, I. A., Al Hage, C., Ismail, D., Zhour, M., Mwesigwa, P., & Darwiche, N. (2026). Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities. Biomolecules. https://doi.org/10.3390/biom16091260
Vancouver
El Moghrabi AA, Al Khatib A, Cheikh IA, Al Hage C, Ismail D, Zhour M, et al. Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities. Biomolecules. 2026. doi:10.3390/biom16091260
BibTeX
@article{ElMoghrabi2026,
author = {El Moghrabi, Alaa A and Al Khatib, Ali and Cheikh, Israa Ahmad and Al Hage, Charbel and Ismail, Dima and Zhour, Mariam and Mwesigwa, Philip and Darwiche, Nadine},
title = {Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16091260}
}
EUVIMED